-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1839100 in Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1839100 in Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1839100 in Pulmonary Fibrosis Drug Details: BI-1839100 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986104 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986104 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986104 in Atopic Dermatitis (Atopic Eczema) Drug Details:BMS-986104 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib s-malate in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib s-malate in Rhabdomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib s-malate in Rhabdomyosarcoma Drug Details: Cabozantinib s-malate (XL184, BMS907351, Cometriq) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Seclidemstat Mesylate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seclidemstat Mesylate in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Seclidemstat Mesylate in Solid TumorDrug Details: Seclidemstat (SP-2577) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Thyroid in Hypothyroidism
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Thyroid in Hypothyroidism report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Thyroid in HypothyroidismDrug Details:Armour thyroid is under development for the treatment of hypothyroidism. The...
-
Company Profile
Salarius Pharmaceuticals Inc – Company Profile
Salarius Pharmaceuticals Inc (Salarius Pharmaceuticals) is a biotechnology company. It develops drugs for pediatric and other cancers. It is investigating its lead compound Seclidemstat for the treatment of ewing sarcoma, myxoid liposarcoma, FET-rearranged sarcomas, hematologic and gynecological cancers. The company is also evaluating SP-3164 and NCE 2nd generation LSD1i (lysine specific demethylase 1) programs against hematological and solid tumors. The company aslo carries out targeted protein inhibition (TPI) and targeted protein degradation (TPD). Salarius Pharmaceuticals is headquartered in Houston, Texas,...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...